We are the creators of Genomtec ID, a mobile platform for genetic diagnostics at the point of patient care. We have just obtained our CE-IVD Mark for the GenomtecID Respiratory Panel 5-Plex (RP5-PLEX) which detects viruses and bacteria causing respiratory tract infections, the only solution of this kind in Europe. See more >>
Genomtec SA has established two special purpose vehicles, GMT ID SA and GMT Genomics SA, in which it holds 100% of the shares. They will receive tangible and intangible assets related to the Genomtec ID platform and the OncoSNAAT project, respectively. Each special purpose vehicle, dedicated to a separate technology segment, can be offered separately […]
The shareholders of Genomtec SA at the Extraordinary General Meeting on 12 March 2025 voted on a resolution to increase the Company’s share capital by issuing 1,542,556 new ordinary bearer shares of series P, with the entire exclusion of the subscription rights of the existing shareholders. Genomtec will gain approximately PLN 11 million (gross) from […]
The company’s shareholder – 5HT FR intends to sell 1.3 million existing shares of the company in a public offering and use the entire amount of the funds raised to acquire shares of the new issue. Genomtec S.A. has called an Extraordinary General Meeting on March 12, 2025, at which the company’s shareholders will vote […]
Genomtec took third place in the 2020 “Maker in China” competition, directly supported by the China-CEEC SME Research Institute Government Organisation, in which over 300 companies from Central and Eastern Europe and China compete. Genomtec ID is attracting the attention of Chinese investors, and the company is reassured that its efforts will be backed by the Chinese government’s anticipated expansion in that market at the local and central level.
Genomtec took second place in the 4th edition of the international competition “China Shenzhen Innovation & Entrepreneurship” and received an award of RMB 650,000 RMB, which is about PLN 400,000. Its innovative Genomtec ID platform beat out international competition with 1,046 projects entered. This win opens up new business and development opportunities on the Chinese market for the Company.
Genomtec wins the “Next Health Investment Pitch” competition organised for Polish companies who want to define economic reality through their innovations via Amgen and ImpactCEE. Amgen has been an international pioneer in biotechnology since 1980 and one of the world leaders in the production of biological medicines.
Genomtec won the “Start Up Med” competition organised by the 4th Health Challenges Congress, a forum for a multi-topic discussion on key issues for healthcare systems in Europe.
Genomtec was one of the five finalists of “InCredibles” – an acceleration program aimed at the most innovative and promising entrepreneurs organised by Kulczyk Investments.
Genomtec won second place in the “Shark Tank” competition organised by New Frontiers in Interventional Cardiology, during an international educational and industry meeting for representatives of medicine and related fields in cardiology, surgery and cardiac/vascular imaging.
Genomtec received a distinction in the “Eagle of Innovation” competition organised by Rzeczpospolita in the category of product and service innovations. In this competition, Rzeczpospolita honours young companies – start-ups – that offer innovative and value-creating products or services.
Genomtec took 1st place as the best non-US start-up participating in HUBweek, an annual innovation festival held since 2014 by The Boston Globe, Harvard University, Massachussetts General Hospital, which brings together the most creative minds that influence art, science, and technology.
Genomtec received a distinction in the competition “Architects of Innovation” in the category of “emerging technologies”, which aims to distinguish companies and institutions that focus on innovative solutions, enter new markets, and are not afraid to be a precursor of new trends.
Genomtec was one of the finalists of the Biomed PFR Academy, an educational initiative for innovative pharmaceutical and medical companies.
Genomtec received a distinction in the competition “Architects of Innovation” in the category of “emerging technologies”, which aims to distinguish companies and institutions that focus on innovative solutions, enter new markets, and are not afraid to be a precursor of new trends.
Miron Tokarski, co-founder and CEO of Genomtec was included on the “Forbes: 30 under 30” list, composed of the most promising young entrepreneurs, innovators, investors, managers, economists and business activists in Poland.
Genomtec won the “CVC Young Innovator Awards” competition organised by MIT Enterprise Forum Poland in the acceleration program for start-ups from Central and Eastern Europe in collaboration with MIT and world leading investment funds, such as CVC Capital, dynamically supporting the company’s development.
Genomtec received the main “Innovation Initiator” award in the “Start-up” category from Newsweek Polska in a competition rewarding and promoting companies and institutions for whom innovation is the primary goal.
Genomtec won a bronze medal in the “Pitch to London” annual competition for the best start-ups from Poland, during which they had the opportunity to present themselves to British experts and investors.
Miron Tokarski ranked 9th among the “Top 50 Creative People in Business”, a year-round program involving the exchange of knowledge, experience and business opportunities, rewarding managers for innovation and unconventional solutions in their business.
Miron Tokarski wins the 2nd edition of the “Young Talents” competition in the “Success in innovation” category organised by the Lower Silesian Capital Club. The “Young Talents” competition aims to promote and appreciate young scientists and students from Lower Silesia who have achieved significant success.
